Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11478115 | 0.86 | APP (0.34) | BLM | |
| SCHEMBL466386 | 0.83 | GRIK1 (0.31) | — | |
| SCHEMBL9279118 | 0.81 | GRIK1 (0.31) | — | |
| SCHEMBL884190 | 0.81 | — | — | |
| SCHEMBL28592838 | 0.79 | BLM (0.41) | LMNASLC6A6CYP2C19BLMGABBR2 | |
| Allylamine SCHEMBL7644044 | 0.78 | ALDH1A1 (0.36) | — | |
| SCHEMBL28914373 | 0.77 | LMNA (0.39) | LMNASLC6A6CYP2C19BLMGABBR2 | |
| Sulfuric Acid SCHEMBL14836674 | 0.77 | LMNA (0.32) | LMNASLC6A6CYP2C19BLMGABBR2 | |
| Phosphoric Acid SCHEMBL2161508 | 0.76 | ANPEP (0.31) | — | |
| SCHEMBL88231 | 0.76 | TP53 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210016310-A1 | Turf Printing and Removal Using Foaming Carrier | DAVIS PETE J (US) | 2021-01-21 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-7256164-B2 | High concentration surfactant compositions and methods | MCINTYRE GROUP, LTD. (US) | 2007-08-14 | — | — | US | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
| WO-2006085149-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | WO | disclosed |
| EP-1546297-A4 | HIGH CONCENTRATION SURFACTANT COMPOSITIONS AND METHODS | MCINTYRE GROUP LTD (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1546297-A2 | HIGH CONCENTRATION SURFACTANT COMPOSITIONS AND METHODS | McINTYRE GROUP, LTD. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050037942-A1 | High concentration surfactant compositions and methods | RHODIA OPERATIONS (FR) | 2005-02-17 | — | — | US | disclosed |
| WO-2004015047-A2 | HIGH CONCENTRATION SURFACTANT COMPOSITIONS AND METHODS | MCINTYRE GROUP, LTD. (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-0089615-B1 | FOAMED INK COMPOSITION AND METHOD OF MAKING THE SAME | FOAMINK COMPANY (US) | 1987-06-24 | — | — | EP | disclosed |
| US-4482648-A | POLYSACCHARIDE | FOAMINK COMPANY, INC. (US) | 1984-11-13 | — | — | US | disclosed |
| EP-0089615-A1 | Foamed ink composition and method of making the same | FOAMINK COMPANY (US) | 1983-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | LMNA 478/4885SLC6A6 2884/4885CYP2C19 4141/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | LMNA 71/4885SLC6A6 2101/4885CYP2C19 3421/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | LMNA 89/4885SLC6A6 2154/4885CYP2C19 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.